Oligonucleotide Chemistry & Therapeutics Symposium14 September 2022 | BST (UTC+1)

An intensive 1-day meeting that delves into the latest in oligonucleotides chemistry, process & analytical development, therapeutics, antisense therapy & a meeting place for experts working within cutting-edge oligo research & therapeutic development.

Our Symposiums are delivered through Swapcard, our market-leading and highly interactive digital event platform. Alongside the live programme, it has a variety of other features to maximise your event experience, including AI-assisted match-making with other delegates, additional resource such as white papers, exhibitor pages allowing you to connect with leading solution providers and a host of On-Demand content.

Download Agenda
Full details on the symposium, including the presentations, topic areas and confirmed speakers can be found in the conference brochure
Book Online
Full Registration for the Oligonucleotide Chemistry & Therapeutics Symposium now open. Please click the button below to register for this event.
LinkedIn Group

Our LinkedIn group aims to foster discussion and collaboration between experts working in proteins, bispecifics, peptides and oligonucleotides

Oligonucleotide Chemistry & Therapeutics Symposium
is sponsored by

Programme

Oligonucleotide Chemistry & Therapeutics Symposium includes...

Attendees representing global pharmaceutical organisations, leading biotech companies and internationally renowned academic institutions working within Oligonucleotides

  • Hear from and meet with the leading figures in the oligonucleotides chemistry, formulation & delivery, development and therapeutics; offering in-depth presentations and new ideas you can use to advance your research
  • Interact with fellow attendees and speakers through in-depth panel discussions and workshops as well as live speaker Q&As
  • Explore case studies pertaining to how oligonucleotides are used in therapeutics
  • Gain a comprehensive understanding of the latest synthesis technologies & analytical development

Agenda at a Glance

Track 1 – Oligo Chemistry, Formulation & Delivery AI/Machine Learning

  • Advanced synthesis technologies
  • Oral delivery of oligos
  • Purification technology development:
         » Freeze-drying
         » Chromatography
  • Impurity analysis

Track 2 – Oligo Therapeutics

  • Case studies from:
         » Oncology
         » Genetic disorders
         » Cardiovascular diseases
         » Rare diseases
  • miRNA therapeutics
  • Antisense oligonucleotide therapeutics

Confirmed Speakers

The Symposium brings together a panel of prominent leaders, engineers and scientists sharing new case studies, innovative data and industry outlook for the future

Below were some of the key speakers of our Virtual Symposium: Oligonucleotides: Chemistry & Therapeutics 2021 Event 

michael keller

Michael Keller

F.Hoffman-La Roche Ltd
chandra-vargeese

Chandra Vargeese

Wave Life Sciences

Punit_Seth

Punit Seth

Ionis Pharmaceuticals

Shalini Andersson

Shalini Andersson

AstraZeneca

Tomas Leek

Tomas Leek

AstraZeneca

Event Features​

Networking and knowledge-sharing is at the heart of what we do. Alongside the innovative programme, attendees can engage in a variety of event features and make the most of participation in a range of virtual, remote experiences. 

Virtual Presentations

Benefit from the insight of our expert speakers via live and pre-recorded presentations

Live Q&As

Interact with fellow attendees and speakers during the live Q&As at the end of each presentation

Digital Networking Opportunities

Connect directly with other registrants of event around the world

We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.

Contact Us:

Copyright Oxford Global Marketing Limited. All rights reserved.

WuXi AppTec.

Headline Sponsor

AB Sciex LLC

Business Developer

ABL Inc, is a leading CDMO and CRO harnessing decades of pioneering science and manufacturing expertise to drive the development of innovative therapies and vaccines. ABL has extensive experience working with diverse organizations – including industry, government, and academic entities – to support their quest in improving public health. ABL Inc. –a subsidiary of the French bioindustrial group Institut Mérieuxwhich fights against infectious diseases and cancers, through the complementary approaches of its companies in the fields of diagnosis, immunotherapy, food safety and nutrition –maintains global GMP facilities meeting U.S. and European regulatory standards, providing cGMP biomanufacture of virus-based oncolytic therapies, gene therapies, vaccines, and protein-based immunotherapeutic products. ABL’s CDMO services include bulk drug substance, live virus fill/finish of drug product, process and assay development, and bioanalytical testing. 

As a CRO, ABL’s immunologists use an integrated array of optimized immunology and molecular laboratory assay platforms, to extract immunological correlates of activity and response in both preclinical studies and clinical trials. To stay informed on the latest updates, please follow us on LinkedInTwitter and Facebook and subscribe to our mailing list.